The Spring 2024 issue of the OSUCCC – James Frontiers magazine includes news, grants, prominent studies, clinical advancements, awards and more. The cover story features an in-depth look at a $20 million federal grant that is helping researchers at the OSUCCC – James Center for Tobacco Research put science behind the FDA’s regulation of tobacco products.
View the complete issue in PDF format
Issue highlights
Flipping big tobacco’s script to improve public health
Ohio State’s Center for Tobacco Research has received a $20 million grant from the U.S. Food and Drug Administration (FDA) and the National Cancer Institute to conduct research that will inform the FDA’s regulation of tobacco products – studies that will improve people’s health and potentially save lives.
Researchers gain NCI grant to study novel Ohio State-developed CAR T-cell therapy for patients with B-cell cancers
A five-year, $3.04 million grant from the National Cancer Institute (NCI) will help researchers at the OSUCCC – James study the effectiveness of a cellular therapy they have developed to more efficiently treat patients with relapsed or refractory (treatment-resistant) B-cell malignancies.
Pelotonia-supported PIIO advances immuno-oncology research
Since an initial pledge of $102 million from the Pelotonia community helped launch the Pelotonia Institute for Immuno-Oncology (PIIO) at the OSUCCC – James in 2019, the PIIO has grown rapidly and is making an impact on cancer research and treatment. Also included are highlights of several other Pelotonia-funded research initiatives.
Ohio State opens large cancer-specific outpatient care facility that also holds region’s first Proton Therapy Center
The James Outpatient Care, a large facility devoted entirely to cancer treatment, holds the OSUCCC – James’ first free-standing outpatient surgery center, several specialty clinics, a clinical trials treatment unit and central Ohio’s first Proton Therapy Center, which is a collaboration between the OSUCCC – James and Nationwide Children’s Hospital to provide the latest radiation therapy to adult and pediatric patients.
Cancer innovation moves forward with opening of Pelotonia Research Center
Named in recognition of Pelotonia’s partnership and philanthropic support for cancer research at the OSUCCC – James, the Pelotonia Research Center is equipped with the spaces, technologies and resources needed for researchers to work across multiple disciplines, including cancer.
Phase II clinical trial gauges effectiveness of drug combination for treating Richter’s syndrome
Patient accrual is underway for a phase II clinical trial at the OSUCCC – James (OSU-22157) that is testing how well zanubrutinib and lisocabtagene maraleucel (liso-cel) work together in treating patients with recurrent or refractory Richter’s syndrome. Richter's syndrome occurs when chronic lymphocytic leukemia and/or small lymphocytic leukemia transforms into an aggressive lymphoma.